Quetiapine fumarate for schizophrenia and bipolar disorder in young patients

M. Ribolsi, V. Magni, Ivo Alex Rubino

Research output: Contribution to journalArticlepeer-review


During the past decade, there has been a substantial increase in the prescribing of antipsychotics to young patients for a variety of pediatric psychiatric disorders. Quetiapine (Seroquel®) received its initial indication from the U.S. Food and Drug Administration for treatment of schizophrenia in 1997, and it received its second indication for the treatment of mania-associated bipolar disorder in 2004. Currently, in young patients, authorized quetiapine indications are schizophrenia in individuals aged 13 or older and manic episodes associated with bipolar I disorder in children 10 to 17 years old. Quetiapine has different pharmacological actions and acts as an antagonist for following receptors: D2 receptor, serotonin 5-HT 2A also known as α1-adrenoceptor, histamine 1 receptor and muscarinic acetylcholine receptor. Several studies have shown its favorable profile of effectiveness and tolerability in young bipolar and schizophrenic patients. However, the current data make it very clear that the risks and benefits of this drug need to be weighed individually for each patient.

Original languageEnglish
Pages (from-to)581-587
Number of pages7
JournalDrugs of Today
Issue number8
Publication statusPublished - Aug 2010

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)


Dive into the research topics of 'Quetiapine fumarate for schizophrenia and bipolar disorder in young patients'. Together they form a unique fingerprint.

Cite this